Fig. 7. TAS4464 exerts strong antitumor activity via activation of both the intrinsic and extrinsic apoptotic pathways accompanied by an increase in the NOXA level and a decrease in the c-FLIP level in a human AML xenograft model.
A TAS4464 (100 mg kg−1) was administered intravenously. Tumors were harvested at the indicated times after administration of TAS4464 and prepared for immunoblotting. B TAS4464 was administered intravenously twice weekly at 100 mg kg−1 per day. Cytarabine was administered intravenously twice a week for 3 weeks at 100 mg kg−1 per day. Data are presented as the mean ± SD values. *P < 0.05 in the treated group compared with the control group (Dunnett’s test).